CytoDyn Inc (OTCMKTS:CYDY) Going Up And Down The Charts

[[tagnumber 0]][[tagnumber 1]]CytoDyn Inc (OTCMKTS:CYDY) embarked on an upward run to recover above the $1 per share mark in the end of last month. It not only managed to do this, but continued to climb higher up the charts while the daily volumes kept rising.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The last time we wrote about the company we mentioned that the current market cap and the intensity of trading might cause a correction sooner, rather than later, and that’s exactly what happened. [[tagnumber 6]]CYDY[[tagnumber 7]] took a slide that cost it some of the value that it had gained, but the ticker managed to hold off at the previous highs, reached in the end of January.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]We reckon that the strengthened balance sheet was one of the things that stopped [[tagnumber 6]]CYDY[[tagnumber 7]] from falling further down the charts. The company filed its report for the quarter ended February 29, 2016 earlier this month and it contained the following numbers of prime interest.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 17]] [[tagnumber 18]]cash: $10.20 million[[tagnumber 19]] [[tagnumber 18]]current assets: $12.21 million[[tagnumber 19]] [[tagnumber 18]]current liabilities: $3.37 million[[tagnumber 19]] [[tagnumber 18]]revenues: ZERO[[tagnumber 19]] [[tagnumber 18]]net loss: $5.04 million[[tagnumber 19]] [[tagnumber 28]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Looking at these numbers we see a few ups and downs. First off, the company has somehow managed to increase its net loss significantly compared to the same period last year. The revenues are still non–existent, but that’s understandable. On the good side of things we see that [[tagnumber 6]]CYDY[[tagnumber 7]] has strengthened its cash positions really well and it has significantly decreased its current liabilities.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Another thing that has happened [[tagnumber 6]]CYDY[[tagnumber 7]] retain most of its gains are the regular optimistic press releases. The latest ones announced that the company has filed a compassionate use protocol for its PRO 140 HIV treatment with the FDA and some positive results in patients treated with it.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]CYDY[[tagnumber 7]] managed to gain 9.13% in the end of last week and climbed to a close at $1.255. A total of 235 thousand traded shares generated $281 thousand in daily dollar volume. Things are heating up today and we already see the volumes surpass those from before the weekend. It seems, however, that this is not having a very positive effect on [[tagnumber 6]]CYDY’s[[tagnumber 7]] price.[[tagnumber 2]]